Adjuvant chemotherapy could benefit patients with localized colorectal cancer (quasar trial)

December 13, 2007

Chemotherapy with fluorouracil and folinic acid could improve survival of patients with stage II colorectal cancer compared with observation alone, although the absolute improvements are small. These are the conclusions of an Article in this week's edition of The Lancet.

Colorectal cancer is the second most common malignant disease in developed countries, with 1 million new cases and 500000 deaths worldwide every year. Cytotoxic chemotherapy after complete resection can lower the risk of recurrence, and flurouracil and folinic acid has become widely used for stage III (node positive) colorectal cancer. However, uncertainty remains regarding the value of this regimen in patients with stage II (node negative) colon cancer. The QUASAR (Quick and Simple and Reliable) trial was designed to provide large-scale randomised evidence on this issue.

Professor Richard Gray, Dr Jennifer Barnwell, and colleagues from the QUASAR Collaborative Group, Cancer Research UK Clinical Trial Unit, University of Birmingham, UK, studied 3239 patients who had had apparently curative resection of colon or rectal cancer, median age 63 years. The patients were recruited from 150 centres in 19 countries between 1994 and 2003. Around half the patients were randomised to receive chemotherapy with fluorouracil and folinic acid, with the other half observation alone. Chemotherapy was delivered as six 5-day courses every 4 weeks or as 30 once-weekly courses of intravenous fluorouracil with high-dose or low dose folinic acid.

The researchers found there were 293 recurrences of cancer in the chemotherapy group and 359 in the observation group, which meant the risk of recurrence was reduced by 22% by chemotherapy compared with observation alone. The numbers of deaths were also reduced, by 18%. The authors conclude: "Chemotherapy with flurouracil and folinic acid could improve survival of patients with stage II colorectal cancer, although the absolute improvements are small: assuming 5-year mortality without chemotherapy is 20%, the relative risk of death seen here translates into an absolute improvement in survival of 3.6%."

In an accompanying Comment, Professor David Cunningham and Dr Naureen Starling, Royal Marsden Hospital, Sutton, Surrey, UK, say: "The decision to treat stage II colorectal cancer should be taken with the patient after consideration of the size of the benefit versus potential toxic effects." They also discuss the importance of identification of the patients most likely to benefit from therapy, and novel techniques in continuing development for this purpose, for example molecular markers.
The paper associated with this release can be found at

Professor David Cunningham, Royal Marsden Hospital, Sutton, Surrey, UK. T) +44 (0) 20 8661 3156 E)

Ben Hill, Press Officer University of Birmingham, UK T) +44 (0) 121 4145134 /+44 (0) 7789 921 163 E)

Professor David Cunningham, Royal Marsden Hospital, Sutton, Surrey, UK. T) +44 (0) 20 8661 3156 E)


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to